Vazquez Chris 4

4 · BIODESIX INC · Filed Jan 20, 2026

Form 4

Period: 2026-01-15

Chief Accounting Officer

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-01-15+219→ 1,155 total
Sale
Common Stock
[F2][F3]
2026-01-16$8.15/sh−83$676→ 1,072 total
Exercise/Conversion
Restricted Stock Units
[F1][F4][F5]
2026-01-15−219→ 436 total
→ Common Stock (219 underlying)

Footnotes (5)

[F1]Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
[F2]These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs.
[F3]The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $8.10 to $8.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F4]These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025.
[F5]These RSUs vest in a series of four successive equal annual installments measured from January 15, 2024, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

Signature

/s/ Robin H. Cowie as Attorney-in-Fact for Chris Vazquez|2026-01-20

Documents

1 file